Baxter International has filed a patent for a control system that operates an apparatus for extracorporeal blood processing. The system extracts, processes, and returns blood while removing fluid based on a set value for ultrafiltration rate (UFR). The control system obtains sensor data representing physiological parameters of the individual and performs an optimization procedure to generate the set value. This procedure involves evaluating the sensor data, sequentially controlling the apparatus, and updating the set value. The control system can perform multiple optimization procedures during a treatment session to adapt the UFR to the individual. GlobalData’s report on Baxter International gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Baxter International, remote monitored dialysis machines was a key innovation area identified from patents. Baxter International's grant share as of September 2023 was 59%. Grant share is based on the ratio of number of grants to total number of patents.
Control system for optimizing ultrafiltration rate during blood processing
A recently filed patent (Publication Number: US20230310723A1) describes a control system for an extracorporeal blood processing apparatus. The control system includes one or more processors and a computer-readable medium with computer logic that controls the apparatus during a treatment session. The system is designed to draw blood from an individual, pump it through a blood filter arrangement, and return it to the individual while removing fluid from the blood based on a set value for ultrafiltration rate. The system also takes input from sensors that measure physiological parameters of the individual.
During the treatment session, the control system performs an optimization procedure intermittently to generate the set value for ultrafiltration rate. This optimization procedure involves evaluating the sensor data to detect a limiting physiological status (LPS) of the individual. The system then sequentially controls the blood processing apparatus to achieve different ultrafiltration rates until the LPS is detected for a specific rate. The set value is then updated based on this current ultrafiltration rate for use in the rest of the treatment session.
The evaluation of sensor data is done after a stabilization period from the initiation of each ultrafiltration rate. The sequence of ultrafiltration rates is ordered by increasing magnitude, starting from a minimum value. If the sensor data indicates the LPS for the minimum value, the set value is updated to a predetermined value below the minimum value, which corresponds to an ultrafiltration rate of zero.
The control system can autonomously initiate the optimization procedure during the treatment session. It can also initiate the procedure at a predetermined time interval or as a function of the sensor data or the set value generated by the previous optimization procedure. The system can perform multiple optimization procedures during the treatment session, with the minimum value for ultrafiltration rate being the same in each procedure.
The patent also describes an extracorporeal blood processing apparatus that includes a pumping arrangement and the aforementioned control system. The pumping arrangement draws blood from an individual, pumps it through a blood filter arrangement, and returns it to the individual while removing fluid based on the set value for ultrafiltration rate. The control system controls the pumping arrangement and takes input from sensors to perform the optimization procedure.
In summary, this patent describes a control system and method for an extracorporeal blood processing apparatus that optimizes the ultrafiltration rate based on sensor data and a limiting physiological status of the individual. The system performs an intermittent optimization procedure during the treatment session to generate the set value for ultrafiltration rate, ensuring the safety and effectiveness of the blood processing procedure.
To know more about GlobalData’s detailed insights on Baxter International, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
